- Home
- TIL vs KUKE Comparison
TIL vs KUKE Comparison
Compare TIL & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- KUKE
- Stock Information
- Founded
- TIL 2018
- KUKE 2002
- Country
- TIL United States
- KUKE China
- Employees
- TIL N/A
- KUKE N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- TIL Health Care
- KUKE Real Estate
- Exchange
- TIL Nasdaq
- KUKE Nasdaq
- Market Cap
- TIL 230.1M
- KUKE 86.8M
- IPO Year
- TIL 2021
- KUKE 2021
- Fundamental
- Price
- TIL $23.81
- KUKE $2.98
- Analyst Decision
- TIL Buy
- KUKE
- Analyst Count
- TIL 5
- KUKE 0
- Target Price
- TIL $119.00
- KUKE N/A
- AVG Volume (30 Days)
- TIL 334.3K
- KUKE 8.9K
- Earning Date
- TIL 08-12-2025
- KUKE 07-31-2025
- Dividend Yield
- TIL N/A
- KUKE N/A
- EPS Growth
- TIL N/A
- KUKE N/A
- EPS
- TIL N/A
- KUKE N/A
- Revenue
- TIL N/A
- KUKE $9,442,397.00
- Revenue This Year
- TIL N/A
- KUKE N/A
- Revenue Next Year
- TIL N/A
- KUKE N/A
- P/E Ratio
- TIL N/A
- KUKE N/A
- Revenue Growth
- TIL N/A
- KUKE N/A
- 52 Week Low
- TIL $9.62
- KUKE $1.45
- 52 Week High
- TIL $92.00
- KUKE $17.50
- Technical
- Relative Strength Index (RSI)
- TIL 45.83
- KUKE 39.72
- Support Level
- TIL $20.60
- KUKE $2.95
- Resistance Level
- TIL $31.67
- KUKE $3.03
- Average True Range (ATR)
- TIL 3.53
- KUKE 0.11
- MACD
- TIL -1.54
- KUKE 0.03
- Stochastic Oscillator
- TIL 17.93
- KUKE 21.43
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.